| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-81081-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-81031-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-12037-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35032-10ug | |||
| Carrier-Free | NBP2-35032-1mg | |||
| Carrier-Free | NBP2-35032-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35220-10ug | |||
| Carrier-Free | NBP2-35220-1mg | |||
| Carrier-Free | NBP2-35220-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-61126-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-81109-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-81270SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35241-1mg | |||
| Carrier-Free | NBP2-35241-100ug | |||
| Carrier-Free | NBP2-35241-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35121-10ug | |||
| Carrier-Free | NBP2-35121-1mg | |||
| Carrier-Free | NBP2-35121-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-52687-0.025mg | |||
![Immunocytochemistry/Immunofluorescence: IL-7R alpha/CD127 Antibody (YIL7R323) [NBP2-81081] - Immunofluorescence staining of fixed human peripheral blood monocytes (PBMs) with IL-7R alpha/CD127 Antibody (YIL7R323) [NBP2-81081]. Immunofluorescence analysis of paraformaldehyde fixed human PBMs on Shi-fix coverslips, permeabilized with 0.15% Triton and stained with the chimeric rabbit IgG version of YIL7R323 [NBP2-81081] at 10 ug/ml for 1h followed by Alexa Fluor 488 secondary antibody (1 ug/ml), showing membrane staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom NBP2-81081, DAPI, merged channels and an isotype control. The isotype control was stained with an anti-Fluorescein antibody followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/IL-7R-alpha-CD127-Antibody-YIL7R323-Immunocytochemistry-Immunofluorescence-NBP2-81081-img0001.jpg "Immunocytochemistry/Immunofluorescence: IL-7R alpha/CD127 Antibody (YIL7R323) [NBP2-81081] - Immunofluorescence staining of fixed human peripheral blood monocytes (PBMs) with IL-7R alpha/CD127 Antibody (YIL7R323) [NBP2-81081]. Immunofluorescence analysis of paraformaldehyde fixed human PBMs on Shi-fix coverslips, permeabilized with 0.15% Triton and stained with the chimeric rabbit IgG version of YIL7R323 [NBP2-81081] at 10 ug/ml for 1h followed by Alexa Fluor 488 secondary antibody (1 ug/ml), showing membrane staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom NBP2-81081, DAPI, merged channels and an isotype control. The isotype control was stained with an anti-Fluorescein antibody followed by Alexa Fluor 488 secondary antibody.")
![Immunocytochemistry/Immunofluorescence: CD3 epsilon Antibody (OKT-3 (muromonab)) [NBP2-81031] - Immunofluorescence staining of fixed Molt4 cells with CD3 epsilon Antibody (OKT-3 (muromonab)) [NBP2-81031]. Immunofluorescence analysis of paraformaldehyde fixed Molt4 cells on Shi-fix coverslips, permeabilized with 0.15% Triton and stained with the chimeric rabbit IgG version of OKT-3 [NBP2-81031] at 10 ug/ml for 1h followed by Alexa Fluor 488 secondary antibody (1 ug/ml), showing membrane staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom NBP2-81031, DAPI, merged channels and an isotype control. The isotype control was stained with an anti-Fluorescein antibody followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/CD3-epsilon-Antibody-OKT-3-muromonab-Immunocytochemistry-Immunofluorescence-NBP2-81031-img0001.jpg "Immunocytochemistry/Immunofluorescence: CD3 epsilon Antibody (OKT-3 (muromonab)) [NBP2-81031] - Immunofluorescence staining of fixed Molt4 cells with CD3 epsilon Antibody (OKT-3 (muromonab)) [NBP2-81031]. Immunofluorescence analysis of paraformaldehyde fixed Molt4 cells on Shi-fix coverslips, permeabilized with 0.15% Triton and stained with the chimeric rabbit IgG version of OKT-3 [NBP2-81031] at 10 ug/ml for 1h followed by Alexa Fluor 488 secondary antibody (1 ug/ml), showing membrane staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom NBP2-81031, DAPI, merged channels and an isotype control. The isotype control was stained with an anti-Fluorescein antibody followed by Alexa Fluor 488 secondary antibody.")
![ELISA: CD96 Antibody (6A6) - Chimeric [NBP3-12037] - Binding curve of the rabbit chimeric version of the anti-CD96 antibody 6A6 (blue line) to an ELISA plate coated with mouse CD96-Fc fusion protein at a concentration of 5 ug/ml. A 3-fold serial dilution from 10000 to 1.7 ng/ml was performed using NBP3-12037. For signal detection, a 1:4000 dilution of anti-rabbit IgG1 HRP antibody was used.](http://images.novusbio.com/fullsize/CD96-Antibody-6A6-Chimeric-ELISA-NBP3-12037-img0001.jpg "ELISA: CD96 Antibody (6A6) - Chimeric [NBP3-12037] - Binding curve of the rabbit chimeric version of the anti-CD96 antibody 6A6 (blue line) to an ELISA plate coated with mouse CD96-Fc fusion protein at a concentration of 5 ug/ml. A 3-fold serial dilution from 10000 to 1.7 ng/ml was performed using NBP3-12037. For signal detection, a 1:4000 dilution of anti-rabbit IgG1 HRP antibody was used.")
![SDS-Page: Human IL-16 130 a.a Protein [NBP2-35032]](http://images.novusbio.com/fullsize/Human-IL-16-130-a.a-Protein-SDS-Page-NBP2-35032-img0001.jpg "SDS-Page: Human IL-16 130 a.a Protein [NBP2-35032]")
![SDS-Page: Recombinant Rat IL-13 Protein [NBP2-35220]](http://images.novusbio.com/fullsize/Recombinant-Rat-IL-13-Protein-SDS-Page-NBP2-35220-img0002.jpg "SDS-Page: Recombinant Rat IL-13 Protein [NBP2-35220]")
![Western Blot: IL-4 Antibody (V17P1B4*B12) [Ovalbumine] - Azide and BSA Free [NBP2-61126] - Western blot image showing detection of recombinant IL4-4B1 (200 ng) using Anti-IL4-4B1 [V17P1B4*B12] at 1/2 dilution. Arrow indicates a correct band of 18 KDa.](http://images.novusbio.com/fullsize/IL-4-Antibody-V17P1B4-B12-Ovalbumine-Azide-and-BSA-Free-Western-Blot-NBP2-61126-img0001.jpg "Western Blot: IL-4 Antibody (V17P1B4*B12) [Ovalbumine] - Azide and BSA Free [NBP2-61126] - Western blot image showing detection of recombinant IL4-4B1 (200 ng) using Anti-IL4-4B1 [V17P1B4*B12] at 1/2 dilution. Arrow indicates a correct band of 18 KDa.")
![Western Blot: CCR4 Antibody (KW-0761 (Mogamulizumab)) - Chimeric [NBP2-81270] - Western Blot using CCR4 Antibody (KW-0761 (Mogamulizumab)) [NBP2-81270]. Human brain cerebellum (A) and human heart (B) lysates (35ug protein in RIPA buffer) were resolved on a 10% SDS PAGE gel and blots probed with the chimeric rabbit IgG version of KW-0761 [NBP2-81270] at 2 ug/ml before detection using an anti-rabbit secondary antibody. A primary incubation of 1h was used and protein was detected by chemiluminescence. The expected running size for CCR4 is 37.7kDa.](http://images.novusbio.com/fullsize/CCR4-Antibody-KW-0761-Mogamulizumab-Chimeric-Western-Blot-NBP2-81270-img0001.jpg "Western Blot: CCR4 Antibody (KW-0761 (Mogamulizumab)) - Chimeric [NBP2-81270] - Western Blot using CCR4 Antibody (KW-0761 (Mogamulizumab)) [NBP2-81270]. Human brain cerebellum (A) and human heart (B) lysates (35ug protein in RIPA buffer) were resolved on a 10% SDS PAGE gel and blots probed with the chimeric rabbit IgG version of KW-0761 [NBP2-81270] at 2 ug/ml before detection using an anti-rabbit secondary antibody. A primary incubation of 1h was used and protein was detected by chemiluminescence. The expected running size for CCR4 is 37.7kDa.")
![SDS-Page: Recombinant Human IL-2 [ Cys Ser125]Protein [NBP3-07100] - Western blot under reducing and non-reducing conditions](http://images.novusbio.com/fullsize/Recombinant Human IL-2 [ Cys Ser125]Protein-SDS-Page-NBP3-07100-img0001.jpg "SDS-Page: Recombinant Human IL-2 [ Cys Ser125]Protein [NBP3-07100] - Western blot under reducing and non-reducing conditions")
![SDS-Page: Rat IL-21 Protein [NBP2-35241]](http://images.novusbio.com/fullsize/Rat-IL-21-Protein-SDS-Page-NBP2-35241-img0001.jpg "SDS-Page: Rat IL-21 Protein [NBP2-35241]")
![SDS-Page: Mouse IL-21 Protein [NBP2-35121]](http://images.novusbio.com/fullsize/Mouse-IL-21-Protein-SDS-Page-NBP2-35121-img0001.jpg "SDS-Page: Mouse IL-21 Protein [NBP2-35121]")
![Flow Cytometry: OX40 Ligand/TNFSF4 Antibody (R4930 (Oxelumab)) - Chimeric [NBP2-52687] - Human peripheral blood leukocytes were fixed using 2% PFA, permeabilised using 0.5% Triton and stained with unimmunized rabbit IgG antibody (isotype control, black line) or the rabbit IgG-chimeric version of R4930 (NBP2-52687, blue line) at a dilution of 1:100 for 1h at RT. After washing, bound antibody was detected using a goat anti-rabbit IgG AlexaFluor 488 antibody at a dilution of 1:1000 and cells analyzed using a FACSCanto flow-cytometer.](http://images.novusbio.com/fullsize/OX40-Ligand-TNFSF4-Antibody-R4930-Oxelumab-Chimeric-Flow-Cytometry-NBP2-52687-img0001.jpg "Flow Cytometry: OX40 Ligand/TNFSF4 Antibody (R4930 (Oxelumab)) - Chimeric [NBP2-52687] - Human peripheral blood leukocytes were fixed using 2% PFA, permeabilised using 0.5% Triton and stained with unimmunized rabbit IgG antibody (isotype control, black line) or the rabbit IgG-chimeric version of R4930 (NBP2-52687, blue line) at a dilution of 1:100 for 1h at RT. After washing, bound antibody was detected using a goat anti-rabbit IgG AlexaFluor 488 antibody at a dilution of 1:1000 and cells analyzed using a FACSCanto flow-cytometer.")